| Abstrakt: |
Sobi and Enable Injections have announced an agreement to develop and distribute Aspaveli in combination with enFuse in Sobi territories. The enFuse Injector, produced by Enable and distributed by Sobi, is designed to improve patients' self-administration experience with minimal disruption to their daily lives. This partnership aims to expand patient choice, enhance comfort, and support adherence, ultimately leading to better health outcomes. The availability of Aspaveli with enFuse technology could offer a simplified treatment experience for more patients, and enFuse may potentially be the first subcutaneous drug delivery device of its kind outside of the U.S. [Extracted from the article] |
